- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01799057
The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication
Study Overview
Status
Intervention / Treatment
Detailed Description
Background and Rationale:
Metformin has demonstrable efficacy in slowing or reversing the progression of various insulin-resistant disease states - most notably type 2 diabetes and pre-diabetes. In seeking to establish proof-of-concept that insulin resistance is a suitable pathophysiological target in the treatment of PAD-related intermittent claudication (pain in the leg muscles during walking, which resolves on exercise cessation), this study will determine whether the known insulin-sensitizing effects of metformin translate to alleviation of the functional limitations imposed by claudication.
Study Design:
A total of 80 individuals with PAD-related intermittent claudication will be randomised (1:1) to either metformin or matching placebo for 16-18 weeks (double-blind, parallel group design). The maximum daily dose of metformin will be 2000mg (up-titrated from half this dose at 2 weeks if tolerated).
Primary Hypothesis:
Improvement in functional capacity follows metformin therapy in individuals with PAD-related intermittent claudication. Change in functional capacity will be assessed by the co-primary endpoints of pain-free and maximum walking times during a standard graded treadmill exercise test.
Secondary Aims:
Exercise testing for functional performance will be complemented by assessments of perceived physical functioning / quality of life in the daily life setting (using standard questionnaires). As previous studies have indicated cardiovascular effects of metformin incremental to blood glucose-lowering, this study will also investigate potential mechanisms of efficacy relating to the primary endpoints, including changes in endothelial function, blood flow responses to various stimuli (including insulin and acute exercise), insulin sensitivity, and physical activity / sedentary behaviours. Changes in relevant clinical data (including ankle-brachial index and limb hemodynamics by duplex scanning) will also be determined.
Outcomes and Significance:
The unmet clinical need of efficacious medical therapies for intermittent claudication is a growing problem given the increasing prevalence of PAD worldwide. If positive, this study will identify a new potential treatment that is already widely available. The study will also inform on novel mechanistic targets with relevance to existing and future therapeutic strategies.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Baker IDI Heart and Diabetes Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥40 years old.
- Resting ankle-brachial index (ABI) ≤0.90 in the limiting leg(s), or a >20% reduction in the ABI measured immediately post-exercise where the resting ABI is >0.90. In cases of incompressible arteries in the limiting leg(s) (i.e. ABI ≥1.40), a toe-brachial index (TBI) of ≤0.70 is required.
- Peripheral artery stenosis/occlusion in the limiting leg(s), documented by duplex ultrasonography or other imaging tests.
- Stable (i.e. 3-month history) intermittent claudication in at least one PAD-affected leg.
- Maximum walking time during graded treadmill exercise testing (Gardner-Skinner protocol) ≥1 minute and ≤16 minutes.
- Concurrent medications that may affect primary, secondary or exploratory endpoints have remained stable over the previous 3 months.
- Have given signed informed consent to participate in the study.
Exclusion Criteria:
- Identification of any other medical condition requiring immediate therapeutic intervention.
- Clinically significant abnormal electrocardiogram (ECG) at rest or during exercise that represents a contraindication to study procedures or the study drug.
- Myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft surgery (CABG), or other major surgery within the previous 6 months.
- Exercise capacity limited by a factor other than PAD-related intermittent claudication.
- Any condition that precludes valid completion of a treadmill exercise test.
- Critical limb ischemia in either leg, defined as PAD-related chronic ischemic rest pain or skin lesions (ulcers, gangrene).
- Previous peripheral revascularisation or other surgical treatment for PAD in the previous 6 months.
- Known non-atherosclerotic cause of PAD.
- Active cancer.
- Uncontrolled hypertension (resting brachial blood pressure ≥160/100 mmHg).
- Evidence of pharmacologically-treated or poorly controlled (i.e. HbA1c ≥7.5%) type 2 diabetes or other class of diabetes (e.g. type 1 diabetes).
- Known intolerance or contraindication(s) to metformin.
- Known contraindication(s) to "Definity" (perflutren lipid microsphere).
- Participation or intention to participate in another clinical research study during the study period.
- History of non-compliance to medical regimens or unwillingness to comply with the study protocol.
- Any other condition that in the opinion of the Investigators would confound the evaluation and interpretation of the data.
- Persons directly involved in the execution of the protocol.
- Incapable of providing written informed consent due to cognitive, language, or other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Metformin
Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e.
maximum of 2000mg per day).
|
Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e.
1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks).
Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Matching placebo twice daily for 16-18 weeks.
|
Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain-free walking time
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Pain-free walking time (time to onset of claudication) will be measured during a graded treadmill exercise test.
|
Measured at baseline and following 16-18 weeks treatment
|
Change in maximum walking time
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Maximum walking time will be measured during a graded treadmill exercise test.
|
Measured at baseline and following 16-18 weeks treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in questionnaire-based markers of quality of life / perceived functional capacity
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Change in endothelial function
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Change in skeletal muscle blood flow response to insulin
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Change in skeletal muscle blood flow response to acute exercise
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Change in insulin sensitivity
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Change in objectively measured physical activity / sedentary behaviour in the daily life setting.
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in glucose uptake and insulin signalling mechanisms in skeletal muscle (exploratory endpoint)
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Change in skeletal muscle oxidative capacity and substrate utilization (exploratory endpoint)
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Change in inflammation, fibrinolysis and coagulation (exploratory endpoint)
Time Frame: Measured at baseline and following 16-18 weeks treatment
|
Measured at baseline and following 16-18 weeks treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bronwyn A Kingwell, PhD, Baker Heart and Diabetes Institute
- Principal Investigator: Stephen J Duffy, MD, PhD, Baker Heart and Diabetes Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Exercise
- Vascular Diseases
- Cardiovascular Diseases
- Quality of Life
- Insulin Resistance
- Atherosclerosis
- Metformin
- Blood Glucose
- Physical Fitness
- Hemorheology
- Microcirculation
- Peripheral Arterial Disease
- Hypoglycemic Agents
- Sedentary Lifestyle
- Endothelium, Vascular
- Plethysmography
- Peripheral Vascular Diseases
- Intermittent Claudication
- Exercise Test
- Glucose Metabolism
- Arterial Occlusive Diseases
- Regional Blood Flow
- Biguanides
- Blood Circulation
Additional Relevant MeSH Terms
Other Study ID Numbers
- 493/12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland